Thanks to Amgen biosim settlement, AbbVie’s $20B Humira forecast looks real
admin 28th September 2017 Uncategorised 0AbbVie’s assertion that Humira will sail clear for several years gained strength on Thursday as the drugmaker inked a patent settlement with Amgen, holding off that company’s biosimilar until 2023.
More: Thanks to Amgen biosim settlement, AbbVie’s B Humira forecast looks real
Source: fierce